Erratum: St John's wort extract (Ze 117) does not alter the pharmacokinetics of a low-dose oral contraceptive (European Journal of Clinical Pharmacology (2009) 65 (287-294) DOI: 10.1007/s00228-008-0587-2);St John's wort extract (Ze 117) does not alter the pharmacokinetics of a low-dose oral contraceptive

European Journal of Clinical Pharmacology

Volumn 65, Issue 3, 2009, Pages 287-294

  Will Shahab, Liane ^a   Bauer, Steffen ^b   Kunter, Ullrich ^a   Roots, Ivar ^b   Brattström, Axel ^c  

^a BIOPHARM   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Max Zeller Sohne AG   (Switzerland)

Author keywords

3 Ketodesogestrel; Ethinylestradiol; Hyperforin; Hypericum perforatum; Interaction; St John's wort; Ze 117

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DESOGESTREL PLUS ETHINYLESTRADIOL; ETONOGESTREL; FOLLITROPIN; HYPERFORIN; HYPERICIN; HYPERICUM PERFORATUM EXTRACT; LUTEINIZING HORMONE; ORAL CONTRACEPTIVE AGENT; SEX HORMONE BINDING GLOBULIN; UNCLASSIFIED DRUG; ZE 117;

ADULT; ARTICLE; BLOOD SAMPLING; CAUCASIAN; DEPRESSION; DRUG BLOOD LEVEL; DRUG DISPOSITION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HERBAL MEDICINE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORMONE BLOOD LEVEL; HUMAN; HYPERICUM PERFORATUM; LOW DRUG DOSE; MASS SPECTROMETRY; NORMAL HUMAN; ORAL CONTRACEPTION; PRIORITY JOURNAL;

EID: 60549099725     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-009-0649-0     Document Type: Erratum

References (44)

1. K Linde G Ramirez CD Mulrow A Pauls W Weidenhammer D Melchart 1996 St John's wort for depression - an overview and meta-analysis of randomized clinical trials BMJ 313 253 258
2. A Johne J Brockmöller S Bauer A Maurer M Langheinrich I Roots 1999 Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum) Clin Pharmacol Ther 66 338 345
3. A Maurer A Johne S Bauer J Brockmöller F Donath I Roots M Langheinrich WD Hübner 1999 Interaction of St John's wort extract with phenprocoumon Eur J Clin Pharmacol 55 A22
4. H Nebel BJ Schneider RK Baker DJ Kroll 1999 Potential metabolic interaction between St John's wort and theophylline Ann Pharmacother 33 502
5. A Johne J Schmider J Brockmöller AM Stadelmann E Störmer S Bauer G Scholler M Langheinrich I Roots 2002 Decreased plasma levels of amitriptyline and its metabolites on co-medication with an extract from St. John's wort (Hypericum perforatum) J Clin Psychopharmacol 22 1 46 54
6. I Mai H Krüger K Budde A Johne J Brockmöller HH Neumayer I Roots 2000 Hazardous pharmacokinetic interaction of St John's wort with the immunosuppressant ciclosporin Int J Clin Pharmacol Ther 38 10 500 502
7. SC Piscitelli AH Burstein D Chaitt RM Alfaro J Falloon 2000 Indinavir concentrations and St John's wort [letter] Lancet 355 547 548
8. EMEA 2000 Public statement on the risk of drug interactions with Hypericum perforatum (St John's wort) and antiretroviral medicinal products Lancet 355 547 548
9. KO Hiller AH Schmidt 2000 Chargenkonformität von Phytopharmaka DAZ 25 2955 2961
10. M Wurglics K Westerhoff A Kaunzinger A Wilke A Baumeister M Schubert-Zsilavecz 2000 Johanniskrautpräparate DAZ 34 3904 3910
11. SC Mueller B Uehleke H Woehling M Petzsch AK Riethling B Drewelow 2000 Intraction of digoxin and herbal extracts from St John's wort depends on dose and formulation Eur J Clin Pharmacol 56 6/7 A16
12. SC Mueller B Uehleke H Woehling M Petzsch J Majcher-Peszynska EV Hehl H Sievers B Frank AK Reithling B Drewelow 2004 Effect of St John's wort dose and preparations on the pharmacokinetics of digoxin Clin Pharmacol Ther 75 546 557
13. I Mai S Bauer ES Perloff A Johne B Uehleke B Frank K Budde I Roots 2004 Hyperforin content determines the magnitidue of the St John's wort-cyclosporine drug interaction Clin Pharmacol Ther 76 330 340
14. B Meier 2001 Comparing phytopharmaceuticals: the example of St John's wort Adv Ther 18 35 46
15. E Schrader B Meier A Brattström 1998 Hypericum treatment of mild-moderate depression in a placebo-controlled study. A prospective, double-blind, randomized, placebo-controlled, multicentre study Hum Psychopharmacol 13 163 169
16. E Schrader 2000 Equivalence of St John's wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression Int Clin Psychopharmacol 15 61 68
17. H Woelk 2000 Comparison of St John's wort and imipramine for treating depression: randomised controlled trial BMJ 321 536 539
18. JW Budzinski BC Foster S Vanderhoek JT Arnasom 2000 An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures Phytomedicine 7 273 282
19. LB Moore B Goodwin SA Kones GB Wisely CJ Serabit-Singh TM Willson JL Collins SA Kliewer 2000 St John's wort induces hepatic drug metabolism through activation of the pregnane X receptor PNAS 97 7500 7502
20. RS Obach 2000 Inhibition of human cytochrome P450 enzymes by constituents of St John's wort, an herbal preparation used in the treatment of depression J Phar Exp Ther 294 88 95
21. CA Roby GD Anderson E Kantor DA Dryer AH Burstein 2000 St John's wort: effect on CYP3A4 activity Clin Pharmacol Ther 67 451 457
22. E Ernst 1999 Second thoughts about safety of St John's wort Lancet 354 2014 2016
23. AE Raetz M vonMoos J Drewe 2001 Johanniskraut: ein Phytopharmakon mit potentiell gefährlichen Interaktionen Praxis 90 843 849
24. A Pfrunder M Schiesser S Gerber M Haschke J Bitzer J Drewe 2003 Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial Br J Clin Pharmacol 56 683 690
25. SD Hall Z Wang SM Huang MA Hamman N Vasavada AQ Adigun JK Hilligoss M Miller JC Gorski 2003 The interaction between St John's wort and an oral contraceptive Clin Pharmacol Ther 74 525 535
26. PA Murphy SE Kern FZ Stanczyk CL Westhoff 2005 Interaction of St John's wort with oral contraceptives: effects on the pharmacokinetics of norehindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding Contraception 71 402 408
27. G Arold F Donath A Maurer K Diefenbach S Bauer HH Henneicke-von Zeppelin M Friede I Roots 2005 No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John's wort extract Planta Med 71 4 331 337
28. DL Whitten SP Myers JA Hawrelak H Wohlmuth 2006 The effect of St John's wort extracts on CY3A: a systematic review of prospective clinical trials Br J Clin Pharmacol 62 5 512 526
29. U Gödtel-Armbrust A Metzger U Kroll O Kelber L Wojnowski 2007 Variability in PXR-mediated induction of CYP3A4 by commercial preparations and dry extracts of St John's Wort Naunyn Schmidebergs Arch Pharmacol 375 6 377 382
30. S Bauer E Störmer HJ Graubaum I Roots 2001 Determination of hyperforin, hypericin and pseudohypericin in human plasma using high-performance liquid chromatography analysis with fluorescence and UV detection J Chromatogr B Biomed Sci Appl 765 1 29 35
31. O Hu H Tang H Lane W Chang T Hu 1998 Novel single-point plasma or saliva dextromethorphan method for determining CYP2D6 activity J Pharmacol Exp Ther 285 955 960
32. C Sachse J Brockmöller S Bauer I Roots 1997 Cytochrome P 450 2D6 variants in a Caucasian population: allele frequencies and phenotype consequences Am J Hum Genet 60 284 295
33. KL Rost J Brockmöller F Esdorn I Roots 1995 Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment J Hepatol 23 268 277
34. S Krusekopf I Roots U Kleeber 2003 Differential drug-induced mRNA expression of human CYP3A4 compared to CYP3A5, CY-3A7 and CYP3A43 Eur J Pharmacol 466 7 12
35. Y Böttiger 2006 Use of omeprazole sulfone in a single plasma sample as a probe for CYP3A4 Eur J Clin Pharmacol 62 621 625
36. B Kaplan 1995 Desogestrel, norgestimate, and gestodene: the newer progestins Ann Pharmacother 29 736 742
37. DM Gentile CHJ Verhoeven T Shimada DJ Back 1998 The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel J Pharmacol Exp Ther 287 975 982
38. V DeLeo D Lanzetta AL Vanni D D'Atona FM Severy 1991 Low estrogen oral contraceptives and the hypothalamo-pituitary axis Contraception 44 155 161
39. AM Van Heusden BC Fauser 1999 Activity of the pituitary-ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives Contraception 59 237 243
40. JW Faigle L Schenkel 1998
41. FZ Stanczyk 1997 Pharmacokinetics of the new progestogenes and influence of gestodene and desogestrel on ethinylestradiol metabolism Contraception 55 273 282
42. Ereshefsky B, Gewertz N, Lam YWF, Vega LM, Ereshefsky L (1999) Determination of SJW differential metabolism at CYP2D6 and CYP3A4, using dextromethorphan probe methodology. NCDEU, 39th Ann. Meeting, Boca Raton, Florida, June 1-4, poster No. 130
43. JS Markowitz CL DeVane DW Boulton SW Carson Z Nahas SC Risch 2000 Effect of St John's wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers Life Sci 66 9 133 139
44. SC Müller J Majcher-Peszynska B Uehleke S Klammt RG Mundkowski W Miekisch H Sievers S Bauer B Frank G Kundt B Drewelow 2006 The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose Eur J Clin Pharmacol 62 1 29 36